NR1H4 and metabolic dysfunction-associated steatotic liver disease: Currently, there are many drugs targeting NAFLD in clinical trials, such as the farnesoid X receptor (FXR) agonist obeticholic acid; however, none of them have shown certain therapeutic effects (109).